AAPL333.02+3.62 (+1.10%) ▲|ABBV261.59-1.70 (-0.65%) ▼|ABT98.83-2.12 (-2.10%) ▼|ACN183.37+6.25 (+3.53%) ▲|ADBE239.94+6.77 (+2.90%) ▲|AMAT511.38-0.63 (-0.12%) ▼|AMD611.76+4.19 (+0.69%) ▲|AMGN421.51-2.13 (-0.50%) ▼|AMT163.69-1.87 (-1.13%) ▼|AMZN249.15+2.48 (+1.01%) ▲|AVGO351.19-3.91 (-1.10%) ▼|AXP304.10-1.30 (-0.43%) ▼|BA186.05-1.63 (-0.87%) ▼|BAC54.43-0.53 (-0.96%) ▼|BKNG162.91+0.57 (+0.35%) ▲|BLK1,058.29-9.65 (-0.90%) ▼|BMY62.40-0.46 (-0.73%) ▼|BNY144.63-2.35 (-1.60%) ▼|BRK-B497.95-4.40 (-0.88%) ▼|C129.48-1.32 (-1.01%) ▼|CAT810.79-15.85 (-1.92%) ▼|CL85.32-1.14 (-1.32%) ▼|CMCSA21.76+0.16 (+0.74%) ▲|COF193.07-3.39 (-1.73%) ▼|COP125.15-0.29 (-0.23%) ▼|COST910.34-14.25 (-1.54%) ▼|CRM229.57+4.26 (+1.89%) ▲|CSCO107.63+0.69 (+0.65%) ▲|CVS85.69-1.41 (-1.62%) ▼|CVX204.21-0.17 (-0.08%) ▼|DE671.55-7.33 (-1.08%) ▼|DHR221.55-4.16 (-1.84%) ▼|DIS104.90-0.51 (-0.48%) ▼|DUK114.01-0.20 (-0.18%) ▼|EMR155.10-2.14 (-1.36%) ▼|FDX285.09-2.38 (-0.83%) ▼|GD331.83-0.51 (-0.15%) ▼|GE312.29-5.60 (-1.76%) ▼|GEV950.49-12.00 (-1.25%) ▼|GILD149.05-2.23 (-1.47%) ▼|GM77.00-3.47 (-4.31%) ▼|GOOG340.74+3.42 (+1.01%) ▲|GOOGL344.08+3.16 (+0.93%) ▲|GS900.36-15.88 (-1.73%) ▼|HD284.49-3.55 (-1.23%) ▼|HON210.94+0.81 (+0.39%) ▲|IBM219.93-0.06 (-0.03%) ▼|INTC120.23+4.30 (+3.71%) ▲|INTU275.71+7.68 (+2.87%) ▲|ISRG406.63-5.55 (-1.35%) ▼|JNJ264.74-2.83 (-1.06%) ▼|JPM330.83-4.15 (-1.24%) ▼|KO86.08-0.76 (-0.88%) ▼|LIN474.65+1.28 (+0.27%) ▲|LLY1,157.08-27.55 (-2.33%) ▼|LMT509.25-2.96 (-0.58%) ▼|LOW184.29-2.97 (-1.59%) ▼|LRCX328.51+4.65 (+1.44%) ▲|MA551.47-12.11 (-2.15%) ▼|MCD230.94-3.04 (-1.30%) ▼|MDLZ57.82-0.98 (-1.67%) ▼|MDT86.29-0.80 (-0.92%) ▼|META725.18-13.61 (-1.84%) ▼|MMM164.15-4.34 (-2.58%) ▼|MO67.34-1.38 (-2.01%) ▼|MRK145.31-3.97 (-2.66%) ▼|MS188.08-4.68 (-2.43%) ▼|MSFT512.90+3.94 (+0.77%) ▲|MU1,065.11+0.03 (+0.00%) ▲|NEE75.74-0.15 (-0.20%) ▼|NFLX69.58-0.72 (-1.02%) ▼|NKE35.40-0.44 (-1.23%) ▼|NOW134.01+4.07 (+3.13%) ▲|NVDA228.38+1.17 (+0.51%) ▲|ORCL137.30-0.49 (-0.36%) ▼|PEP126.72-1.97 (-1.53%) ▼|PFE28.52-0.20 (-0.70%) ▼|PG145.28-3.04 (-2.05%) ▼|PLTR187.05+0.08 (+0.04%) ▲|PM190.82-3.08 (-1.59%) ▼|QCOM184.04-0.06 (-0.03%) ▼|RTX185.65-1.29 (-0.69%) ▼|SBUX93.96-1.47 (-1.54%) ▼|SCHW97.74-1.36 (-1.37%) ▼|SO82.89-0.56 (-0.67%) ▼|SPG200.76-3.52 (-1.72%) ▼|T24.40-0.08 (-0.33%) ▼|TMO675.05-4.56 (-0.67%) ▼|TMUS163.08+0.10 (+0.06%) ▲|TSLA354.81+1.97 (+0.56%) ▲|TXN280.09-1.60 (-0.57%) ▼|UBER68.51-0.85 (-1.23%) ▼|UNH367.08-7.86 (-2.10%) ▼|UNP272.13-2.02 (-0.74%) ▼|UPS93.44-0.49 (-0.52%) ▼|USB57.76+0.16 (+0.28%) ▲|V359.33-6.55 (-1.79%) ▼|VZ45.87-0.11 (-0.24%) ▼|WFC80.05-0.43 (-0.53%) ▼|WMT103.92-2.88 (-2.70%) ▼|XOM162.75+1.40 (+0.87%) ▲|AAPL333.02+3.62 (+1.10%) ▲|ABBV261.59-1.70 (-0.65%) ▼|ABT98.83-2.12 (-2.10%) ▼|ACN183.37+6.25 (+3.53%) ▲|ADBE239.94+6.77 (+2.90%) ▲|AMAT511.38-0.63 (-0.12%) ▼|AMD611.76+4.19 (+0.69%) ▲|AMGN421.51-2.13 (-0.50%) ▼|AMT163.69-1.87 (-1.13%) ▼|AMZN249.15+2.48 (+1.01%) ▲|AVGO351.19-3.91 (-1.10%) ▼|AXP304.10-1.30 (-0.43%) ▼|BA186.05-1.63 (-0.87%) ▼|BAC54.43-0.53 (-0.96%) ▼|BKNG162.91+0.57 (+0.35%) ▲|BLK1,058.29-9.65 (-0.90%) ▼|BMY62.40-0.46 (-0.73%) ▼|BNY144.63-2.35 (-1.60%) ▼|BRK-B497.95-4.40 (-0.88%) ▼|C129.48-1.32 (-1.01%) ▼|CAT810.79-15.85 (-1.92%) ▼|CL85.32-1.14 (-1.32%) ▼|CMCSA21.76+0.16 (+0.74%) ▲|COF193.07-3.39 (-1.73%) ▼|COP125.15-0.29 (-0.23%) ▼|COST910.34-14.25 (-1.54%) ▼|CRM229.57+4.26 (+1.89%) ▲|CSCO107.63+0.69 (+0.65%) ▲|CVS85.69-1.41 (-1.62%) ▼|CVX204.21-0.17 (-0.08%) ▼|DE671.55-7.33 (-1.08%) ▼|DHR221.55-4.16 (-1.84%) ▼|DIS104.90-0.51 (-0.48%) ▼|DUK114.01-0.20 (-0.18%) ▼|EMR155.10-2.14 (-1.36%) ▼|FDX285.09-2.38 (-0.83%) ▼|GD331.83-0.51 (-0.15%) ▼|GE312.29-5.60 (-1.76%) ▼|GEV950.49-12.00 (-1.25%) ▼|GILD149.05-2.23 (-1.47%) ▼|GM77.00-3.47 (-4.31%) ▼|GOOG340.74+3.42 (+1.01%) ▲|GOOGL344.08+3.16 (+0.93%) ▲|GS900.36-15.88 (-1.73%) ▼|HD284.49-3.55 (-1.23%) ▼|HON210.94+0.81 (+0.39%) ▲|IBM219.93-0.06 (-0.03%) ▼|INTC120.23+4.30 (+3.71%) ▲|INTU275.71+7.68 (+2.87%) ▲|ISRG406.63-5.55 (-1.35%) ▼|JNJ264.74-2.83 (-1.06%) ▼|JPM330.83-4.15 (-1.24%) ▼|KO86.08-0.76 (-0.88%) ▼|LIN474.65+1.28 (+0.27%) ▲|LLY1,157.08-27.55 (-2.33%) ▼|LMT509.25-2.96 (-0.58%) ▼|LOW184.29-2.97 (-1.59%) ▼|LRCX328.51+4.65 (+1.44%) ▲|MA551.47-12.11 (-2.15%) ▼|MCD230.94-3.04 (-1.30%) ▼|MDLZ57.82-0.98 (-1.67%) ▼|MDT86.29-0.80 (-0.92%) ▼|META725.18-13.61 (-1.84%) ▼|MMM164.15-4.34 (-2.58%) ▼|MO67.34-1.38 (-2.01%) ▼|MRK145.31-3.97 (-2.66%) ▼|MS188.08-4.68 (-2.43%) ▼|MSFT512.90+3.94 (+0.77%) ▲|MU1,065.11+0.03 (+0.00%) ▲|NEE75.74-0.15 (-0.20%) ▼|NFLX69.58-0.72 (-1.02%) ▼|NKE35.40-0.44 (-1.23%) ▼|NOW134.01+4.07 (+3.13%) ▲|NVDA228.38+1.17 (+0.51%) ▲|ORCL137.30-0.49 (-0.36%) ▼|PEP126.72-1.97 (-1.53%) ▼|PFE28.52-0.20 (-0.70%) ▼|PG145.28-3.04 (-2.05%) ▼|PLTR187.05+0.08 (+0.04%) ▲|PM190.82-3.08 (-1.59%) ▼|QCOM184.04-0.06 (-0.03%) ▼|RTX185.65-1.29 (-0.69%) ▼|SBUX93.96-1.47 (-1.54%) ▼|SCHW97.74-1.36 (-1.37%) ▼|SO82.89-0.56 (-0.67%) ▼|SPG200.76-3.52 (-1.72%) ▼|T24.40-0.08 (-0.33%) ▼|TMO675.05-4.56 (-0.67%) ▼|TMUS163.08+0.10 (+0.06%) ▲|TSLA354.81+1.97 (+0.56%) ▲|TXN280.09-1.60 (-0.57%) ▼|UBER68.51-0.85 (-1.23%) ▼|UNH367.08-7.86 (-2.10%) ▼|UNP272.13-2.02 (-0.74%) ▼|UPS93.44-0.49 (-0.52%) ▼|USB57.76+0.16 (+0.28%) ▲|V359.33-6.55 (-1.79%) ▼|VZ45.87-0.11 (-0.24%) ▼|WFC80.05-0.43 (-0.53%) ▼|WMT103.92-2.88 (-2.70%) ▼|XOM162.75+1.40 (+0.87%) ▲|
19.7 C
New York
Thursday, October 1, 2026

Tag: 1

newssourceFORcompanyinformationcontent1releasesmarket

CAR 截止日期提醒：廣受信賴的投資人法律顧問 ROSEN 鼓勵損失超過 10 萬美元的 Avis Budget Group, Inc 投資人於 6 月 24 日證券集體訴訟重要截止日期前聘請律師 – CAR

紐約, June 15, 2025 (GLOBE NEWSWIRE) --

事由：全球投資人權益律師事務所 Rosen Law Firm 提醒在 2024 年 2 月 16 日至 2025 年 2 月 10 日（含首尾兩天，簡稱「集體訴訟期間」）期間購買 Avis Budget Group, Inc. (NASDAQ: CAR) 股票的人士，2025 年 6 月 24 日是重要的首席原告截止日期。

XRP Ledger Payment Volume Skyrockets Over 1,000%, Analysts Expect Similar For Remittix (RTX)

New York, June 15, 2025 (GLOBE NEWSWIRE) -- Surprises are common in the crypto sphere but an unprecedented 1,000% surge in XRP Ledger’s payment volume hits different. It speaks of marvelous things to come. That’s why investors are scrambling to position themselves for maximum ROI when the XRP price booms.

Communiqué : Dupixent a démontré sa supériorité par rapport au Xolair dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant...

EAACI : Le Dupixent a démontré sa supériorité par rapport au Xolair (omalizumab) dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant dans la toute première étude respiratoire de phase 4 en comparaison directe jamais présentée

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase...

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints

Freedom Holding Corp. Reports Fiscal Year 2025 Financial Results

ALMATY, Kazakhstan, June 15, 2025 /PRNewswire/ -- Freedom Holding Corp. (NASDAQ: FRHC), the diversified financial group with operations spanning 22 countries, today reported financial...

IBTA 最終截止日期：享譽全球的律師事務所 ROSEN 鼓勵損失超過 10 萬美元的 Ibotta, Inc. 投資者在該事務所對 IBTA 首次提出證券集體訴訟之重要截止日期 6 月 16 日前聘請律師

紐約, June 15, 2025 (GLOBE NEWSWIRE) --

事因：全球投資者權益律師事務所 Rosen Law Firm 提醒：(1) 根據及／或可追溯至因 Ibotta, Inc.（NYSE: IBTA）於 2024 年 4 月 18 日進行首次公開招股（簡稱「IPO」）所發行之註冊聲明及相關招股章程（統稱「註冊聲明」）而購買該公司證券之人士；或 (2) 於 2024 年 4 月 18 日至 2025 年 2 月 26 日期間（包括首尾兩日，簡稱「集體訴訟期」）購買該公司證券之人士注意，該事務所首次提出證券集體訴訟之重要首席原告截止日期為 2025 年 6 月 16 日。

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy...

CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced three-year follow-up data from the Phase 1 portion of the ongoing Phase 1/2 study in patients with HAE after receiving a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). Results were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held June 13-16 in Glasgow, United Kingdom.

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Fortrea Holdings

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Fortrea To Contact Him Directly To...

Scatec reaches financial close for the 1.1GW solar + 100MW/200MWh BESS Obelisk project

Oslo/Cairo, 15 June 2025: Scatec ASA has reached financial close for the “Obelisk” hybrid solar and battery storage project in Egypt.

Backblaze Investor News: If You Have Suffered Losses in Backblaze, Inc. (NASDAQ: BLZE), You Are Encouraged to Contact The Rosen Law Firm About Your...

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Backblaze, Inc. (NASDAQ: BLZE) resulting from allegations that Backblaze may have issued materially misleading business information to the investing public.

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Translational Data Presented at EACCI Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

D-Bal Max 2025: Exploring the Science and Safety behind a Popular And Legal Dianabol Steroid For Muscle Growth

Glasgow, June 15, 2025 (GLOBE NEWSWIRE) --

In the quest for enhanced athletic performance and muscle growth, many fitness enthusiasts and bodybuilders turn to supplements. D-Bal Max has emerged as a noteworthy option that claims to replicate the muscle-building benefits of anabolic steroids, but with a natural and safer approach.

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for...

Media Release

COPENHAGEN, Denmark; June 15, 2025

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTags1

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers